TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 11.42
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$15.00

30 Apr
2026

0.000

OPEN

$14.80

0.000

HIGH

$15.53

2,711,259

LOW

$14.78

TARGET
$25.84 72.3% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 1.9 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-3.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,246.6 M
Book Value Per Share xxxxxxxxxxxxxxx183.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-26.8 M
Net Profit Margin xxxxxxxxxxxxxxx-0.89 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1.86 %
Return on Invested Capital xxxxxxxxxxxxxxx-0.91 %
Return on Assets xxxxxxxxxxxxxxx-0.67 %
Return on Equity xxxxxxxxxxxxxxx-1.86 %
Return on Total Capital xxxxxxxxxxxxxxx2.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-85.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx28 M
Long Term Debt xxxxxxxxxxxxxxx672 M
Total Debt xxxxxxxxxxxxxxx700 M
Goodwill - Gross xxxxxxxxxxxxxxx298 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx213 M
Price To Book Value xxxxxxxxxxxxxxx6.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx86.8 M
Capex % of Sales xxxxxxxxxxxxxxx6.97 %
Cost of Goods Sold xxxxxxxxxxxxxxx584 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx635 M
Research & Development xxxxxxxxxxxxxxx266 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx, xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

15/04/2026

1

Overweight

$24.60

64.00%

Telix Pharmaceuticals announced the launch of a US$500m convertible bond offer, with Morgan Stanley noting net proceeds are flagged to be used to repurchase existing bonds due in 2029.

The issue is viewed positively as an "overhang" on the stock is being removed, with prior market concerns around the July 2027 existing put option on the current bonds.

Positively, the analyst remarks the 1Q26 result was robust, including a resubmitted new drug application for Pixclara and a collaboration with Regeneron.

Overweight rating with $24.60 target retained. Industry view: In-line. No change to earnings forecasts.

FORECAST
Morgan Stanley forecasts a full year FY26 dividend of 0.00 cents and EPS of 2.99 cents.
Morgan Stanley forecasts a full year FY27 dividend of 0.00 cents and EPS of 17.96 cents.

UBS

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

09/04/2026

1

Buy

$21.80

45.33%

Jarden maintains a Buy rating on Telix Pharmaceuticals with a 21.80 price target following a strong first quarter FY26 trading update.

Revenue growth was driven by continued strength in the precision medicine segment, supporting momentum across the core portfolio.

Full-year revenue guidance of US$950m to US$970m is maintained, with potential upside from upcoming product launches.

While operating costs are expected to increase to support growth, commentary posits the company remains on track toward breakeven over the forecast period.

FORECAST
Jarden forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.90 cents.
Jarden forecasts a full year FY27 dividend of 0.00 cents and EPS of 2.00 cents.
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
Rudi’s View: Best Buys & Conviction Calls

Apr 23 2026 - Rudi's View
2
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
3
Australian Broker Call *Extra* Edition – Apr 20, 2026

Apr 20 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Apr 16, 2026

Apr 16 2026 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 14, 2026

Apr 14 2026 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
2
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
3
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
4
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
5
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
6
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
7
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
8
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
9
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
10
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest